HemaSense is developing a wearable device designed to give clinicians real-time visibility into what’s happening beneath the skin during post-procedural recovery, with a mission to accelerate recovery through actionable clinical insight.
What Key Challenge Is HemaSense Focused on Addressing?
Every year, more than 2.3 million patients undergo life-saving catheter-based procedures that access the cardiovascular system through the femoral artery or vein. Nearly 10% of these patients experience a bleed at the access site during recovery. Today, these bleeding events are typically detected through intermittent visual checks by nursing staff, which means many go unnoticed until they progress to the point of requiring surgical intervention or a blood transfusion.
HemaSense is addressing this gap by enabling earlier detection through a simple wearable device that continuously monitors for blood accumulation beneath the surface of the skin before it becomes visible. By providing early, actionable insight, they aim to help clinicians intervene sooner with less invasive, lower-cost treatments, ultimately improving patient outcomes and accelerating recovery.
How Is HemaSense’s Technology Making a Meaningful Impact?
The HemaSense wearable provides clinicians with real-time visibility into what’s happening beneath the skin at the catheter access site during recovery. To their knowledge, it represents the first non-invasive solution capable of detecting bleeding in this context while also delivering quantitative insight into whether intervention may be needed.
Today, when these bleeds occur, they often result in an additional 2 to 3 days of hospitalization and tens of thousands of dollars in added cost. More importantly, they can significantly impact patient comfort and recovery. By enabling earlier detection, HemaSense has the opportunity to reduce complications, shorten hospital stays, and improve the overall patient experience.
How Has Being Based in Arizona Supported HemaSense’s Growth?
Arizona has been an incredibly supportive environment for building HemaSense, particularly within the medtech community. The ecosystem is very collaborative, and they have benefited directly from organizations like AZBio, the Flinn Foundation, and MDM2, which have helped them build meaningful connections across clinical, investment, and operational networks.
One tangible example is their partnership with a local healthcare system for their first clinical trial, an opportunity that came directly from relationships formed through the Arizona bioscience community. Additionally, because their device relies on custom sensing and electronics, they have been able to leverage local expertise in electronics manufacturing, assembly, and packaging, a significant advantage as they move quickly through development.
What Does the Future Look Like for HemaSense?
HemaSense is at a very exciting stage in its development. After a year and a half of focused technical progress and building out the business, they now have their first commercial units in hand, with additional production underway. They are also initiating their first clinical study, which will provide critical data to further validate the device in real-world patient settings.
Over the next six to eight months, their focus will be on completing the testing and documentation required to support an FDA submission in 2027. What excites them most is the opportunity to bring a new standard of care to post-procedural monitoring, one that gives clinicians better tools and patients better outcomes.
About the Author
Ava Woods
Ava Woods is the Marketing & Communications Intern at AZBio, supporting digital communications, content creation, and member engagement initiatives. In her role, Ava assists with social media management, marketing campaigns, event promotion, and storytelling efforts that highlight Arizona’s growing bioscience community. Connect with Ava
About AZBio Member Spotlights
AZBio Member Spotlights are just one of the ways AZBio is building awareness of the health innovations being developed and delivered across the state of Arizona. Telling Arizona’s Bioscience Story is a key goal of Arizona’s Bioscience Roadmap, the nation’s longest-running statewide strategic plan designed to build a robust bioscience sector. Share and enjoy!